SCHEMBL10246359

SCHEMBL10246359

CCNCc1ccc(F)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
ALDH1A1 P00352 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
CYP2D6 P10635 2/20 0.35
DYRK1A Q13627 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
AURKA O14965 1/20 0.35
ABL1 P00519 1/20 0.35
NTRK1 P04629 1/20 0.35
LCK P06239 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6348675 0.80 CYP11B1 (0.42) CYP11B1CYP11B2ALDH1A1CYP2D6DYRK1A
SCHEMBL17888393 0.78 ALDH1A1 (0.43) LMNAALDH1A1NPSR1TP53POLB
SCHEMBL5833046 0.78 MC4R (0.45) CYP11B1CYP11B2L3MBTL1HDAC1
SCHEMBL7981951 0.78 CXCR4 (0.38) CYP11B1CYP11B2TDP1L3MBTL1CYP2D6
SCHEMBL10282267 0.78 SMN1; SMN2 (0.49) LMNACYP11B1CYP11B2ALDH1A1TP53
SCHEMBL357013 0.77
SCHEMBL7662002 0.77 CYP11B1 (0.40) LMNACYP11B1ALDH1A1NPSR1TP53
SCHEMBL888411 0.77 KDM4E (0.56) LMNAALDH1A1L3MBTL1
SCHEMBL13061262 0.77 KDM1A (0.48) CYP3A4CYP2C19LCKCSF1RPDGFRB
SCHEMBL7993517 0.76 CXCR4 (0.38) CYP11B1CYP11B2L3MBTL1CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046283-A1 COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS AFRAXIS INC. (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046283-A1 COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS PAK2, PAK5, PAK6 LMNA 4498/4885CYP11B1 3199/4885CYP11B2 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.